ow glycemic index diets in type two diabetic subjects treated with oral agents

Completed

• Conditions: Type two Diabetes; Nutritional, Metabolic, Endocrine; Diabetes

• Registration Number: ISRCTN36443696
• Lead Sponsor: Canadian Institutes of Health Research (CIHR) (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2004-07-22
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

1. Men and postmenopausal women with type two diabetes, greater than or equal to 18 years old
2. On oral hypoglycemic agents
3. Have fasting plasma HbA1c concentrations between 6.5 and 8.0%

Exclusion Criteria

1. Diabetic complications: clinically significant gastroparesis, retinopathy, nephropathy, neuropathy, hepatic disease or Coronary Heart Disease (CHD) (major coronary event)
2. Major surgery less than six months prior to randomisation, treatment with insulin, acarbose, steroids, or having serum triglycerides more than or equal to 4.0 mmol/

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment difference in the change in HbA1c accross treatments.

Secondary Outcome Measures

Name	Time	Method
1. Fasting blood glucose<br>2. Fasting insulin<br>3. High sensitivity C-Reactive Protein (hs-CRP)<br>4. Oxidized Low Density Lipoprotein (LDL)<br>5. LDL particle size<br>6. High Density Lipoprotein (HDL)<br>7. Change in body weight or oral hypoglycemic agents